New trials, publications, preprints and grants on this target, month by month.
Trial
IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes.
3 Nov 2026· The journal of prevention of Alzheimer's disease· PUBMED
Publication
Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts.
1 Nov 2026· Endocrinology, diabetes & metabolism· PUBMED
Publication
Challenge-Oriented Decision Tree for Analytical Method Selection in Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Triple Antidiabetic Fixed-Dose Combinations in Pharmaceutical Dosage Forms.
1 Nov 2026· Biomedical chromatography : BMC· PUBMED
Publication
Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
30 Oct 2026· International journal of chronic obstructive pulmonary disease· PUBMED
Publication
Integrating QSAR, molecular dynamics and MM-GBSA to re-rank natural product-derived DPP4 candidates from virtual screening.
29 Oct 2026· SAR and QSAR in environmental research· PUBMED
Publication
Use of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations.
26 Oct 2026· Clinical pharmacology and therapeutics· PUBMED
Publication
Key safety outcomes of SGLT2 inhibitors versus DPP-4 inhibitors in general and vulnerable participants with T2DM: A target trial emulation study.
19 Oct 2026· Diabetic medicine : a journal of the British Diabetic Association· PUBMED
Publication
Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.
16 Oct 2026· Journal of clinical medicine· PUBMED
Publication
Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.
15 Oct 2026· Frontiers in pharmacology· PUBMED
Publication
C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide.
7 Oct 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis.
5 Oct 2026· Diabetology international· PUBMED
Publication
GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.
30 Sept 2026· Drug design, development and therapy· PUBMED
Publication
GLP-1 receptor agonists versus DPP-4 inhibitors after curative resection of hepatocellular carcinoma in patients with type 2 diabetes.
29 Sept 2026· Gut· PUBMED
Publication
Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP-4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation.
28 Sept 2026· Clinical pharmacology and therapeutics· PUBMED
Publication
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
26 Sept 2026· Internal and emergency medicine· PUBMED
Publication
The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.
23 Sept 2026· EClinicalMedicine· PUBMED
Publication
Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.
23 Sept 2026· Advances in therapy· PUBMED
Publication
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.
19 Sept 2026· Internal and emergency medicine· PUBMED
Publication
Proteomic profiling reveals that DPP4 overexpression increases cell adhesion, inhibits cell migration, and restores androgen sensitivity in prostate cancer.
16 Sept 2026· Bioscience reports· PUBMED
Publication
GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.
7 Sept 2026· Journal of neurology· PUBMED
Publication
SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes.
4 Sept 2026· Frontiers in endocrinology· PUBMED
Publication
Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study.
1 Sept 2026· Diabetes, obesity & metabolism· PUBMED
Publication
Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk.
28 Aug 2026· Frontiers in public health· PUBMED
Publication
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
20 Aug 2026· Internal and emergency medicine· PUBMED
Publication
Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes.
17 Aug 2026· Diabetes research and clinical practice· PUBMED
Publication
Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study.
11 Aug 2026· Drug design, development and therapy· PUBMED
Publication
Sex-specific cardiometabolic remodeling induced by DPP-4 inhibition under high-fat diet: insights from cardiac proteomics.
10 Aug 2026· Nutrition, metabolism, and cardiovascular diseases : NMCD· PUBMED
Publication
Glycemic Outcomes After Switching from SGLT2 Inhibitors to DPP-4 Inhibitors in Type 2 Diabetes, with a Comparison of Teneligliptin and Other Agents: A Retrospective Cohort Study.
6 Aug 2026· Medicina (Kaunas, Lithuania)· PUBMED
Publication
Targeting the non-enzymatic function of DPP4 via a nanobody inhibits cerebral cavernous malformation progression.
5 Aug 2026· Journal of nanobiotechnology· PUBMED